watch this space, page-11

26-11-12
""Onty utilizes similar Dendritic Cell Therapy to Prima,therefore the outcome may have an impact on Prima's shareprice and future prospects/confidence moving forward,positive or negative, as did Dendreons fall from grace..............""


Well looks like the outcome of Onty's news was negative, in line with the direction of the trend created by the majority of the market participants, in both stocks. Nothing has changed, the stock remains in a longterm downtrend,bottom of the downtrend channel target remains around 6 cents but the stock is in a downtrend so lower lows are possible. Thanks for the heads up boiler....priceless.

All in my opinion.